Citation

  • Authors: Zhang R. et al.
  • Year: 2021
  • Journal: EMBO Rep
  • Applications: in vivo / siRNA / in vivo-jetPEI

Method

siRNAs against Bclaf1 and control siRNAs were delivered into 7-week-old SPF C57BL/6 mice via intravenous injections using in vivo-jetPEI (Polyplus) according to the manufacturer’s protocol. Complexes injected into tail vein twice, 24h apart.

Abstract

TNF stimulation generates pro-survival signals through activation of NF-κB that restrict the build-in death signaling triggered by TNF. The competition between TNF-induced survival and death signals ultimately determines the fate of a cell. Here, we report the identification of Bclaf1 as a novel component of the anti-apoptotic program of TNF. Bclaf1 depletion in multiple cells sensitizes cells to TNF-induced apoptosis but not to necroptosis. Bclaf1 exerts its anti-apoptotic function by promoting the transcription of CFLAR, a caspase 8 antagonist, downstream of NF-κB activation. Bclaf1 binds to the p50 subunit of NF-κB, which is required for Bclaf1 to stimulate CFLAR transcription. Finally, in Bclaf1 siRNA administered mice, TNF-induced small intestine injury is much more severe than in control mice with aggravated signs of apoptosis and pyroptosis. These results suggest Bclaf1 is a key regulator in TNF-induced apoptosis, both in vitro and in vivo.

Pubmed